TransCode Therapeutics Inc. has announced a new collaboration with Quantum Leap Healthcare Collaborative to evaluate its lead therapeutic candidate, TTX-MC138, as part of the Quantum Leap PRE-I-SPY clinical trial platform. The partnership will launch a Phase 2a dose-expansion clinical trial enrolling up to 45 colorectal cancer patients who are ctDNA positive after standard curative-intent therapy. The trial aims to assess the biological and clinical activity of TTX-MC138 in the Minimal Residual Disease setting, with the goal of improving long-term outcomes and preventing cancer recurrence. This collaboration is expected to accelerate the development of effective, less toxic precision therapies for cancer patients.